Furthermore, we found that several dyclonine analogs were also able to enhance the cytotoxic action of xCT or GSH synthesis inhibitors, suggesting that the covalent inhibition of ALDH enzymes including ALDH3A1 might sensitize sulfasalazine-resistant cancer cells to xCT-targeted therapy. This evidence concerns the gene ALDH3A1 and cancer.